Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug-Reference-Cited by-同舟云学术

Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug

Published:2017-03-07 Issue:5 Volume:45 Page:540-555
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

He Handan,Tran Phi,Gu Helen,Tedesco Vivienne,Zhang Jin,Lin Wen,Gatlik Ewa,Klein Kai,Heimbach Tycho

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference28 articles.

1. BDDCS Applied to Over 900 Drugs

2. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages;Birg;Blood,1992

3. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants;Cancer Chemotherapy and Pharmacology;2024-08-07

2. Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials;Frontiers in Pharmacology;2024-05-17

3. Triazole antifungal drug interactions—practical considerations for excellent prescribing;Journal of Antimicrobial Chemotherapy;2024-04-17

4. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography‐tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia;European Journal of Haematology;2024-01-31

5. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants;Cancer Chemotherapy and Pharmacology;2024-01-25